OA10576A - 3-(5-Tetrazolyl-benzyl) amino-piperidine derivatives and antagonists of tachykinins - Google Patents

3-(5-Tetrazolyl-benzyl) amino-piperidine derivatives and antagonists of tachykinins Download PDF

Info

Publication number
OA10576A
OA10576A OA60801A OA60801A OA10576A OA 10576 A OA10576 A OA 10576A OA 60801 A OA60801 A OA 60801A OA 60801 A OA60801 A OA 60801A OA 10576 A OA10576 A OA 10576A
Authority
OA
OAPI
Prior art keywords
tetrazol
piperidin
methoxy
phenyl
formula
Prior art date
Application number
OA60801A
Other languages
English (en)
Inventor
Brian Evans
Middlemiss David
Naylor Alan
Neil Anthony Pegg
Maria Victoria Vinader
Gerard Martin Paul Giblin
Tania Hubbard
Michael Menteith Hann
Xiao-Qing Lewell
Stephen Paul Watson
Duncan Robert Armour
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319606A external-priority patent/GB9319606D0/en
Priority claimed from GB9326583A external-priority patent/GB9326583D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA10576A publication Critical patent/OA10576A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
OA60801A 1993-09-22 1996-03-21 3-(5-Tetrazolyl-benzyl) amino-piperidine derivatives and antagonists of tachykinins OA10576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939319606A GB9319606D0 (en) 1993-09-22 1993-09-22 Chemical compounds
GB9326583A GB9326583D0 (en) 1993-12-31 1993-12-31 Chemical compounds

Publications (1)

Publication Number Publication Date
OA10576A true OA10576A (en) 2002-06-03

Family

ID=26303560

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60801A OA10576A (en) 1993-09-22 1996-03-21 3-(5-Tetrazolyl-benzyl) amino-piperidine derivatives and antagonists of tachykinins

Country Status (30)

Country Link
US (2) US5703240A (uk)
EP (1) EP0720609B1 (uk)
JP (2) JP2865872B2 (uk)
CN (1) CN1061041C (uk)
AP (1) AP495A (uk)
AT (1) ATE173255T1 (uk)
AU (1) AU681190B2 (uk)
BG (1) BG62169B1 (uk)
CA (1) CA2172529A1 (uk)
CO (1) CO4290298A1 (uk)
CZ (1) CZ285479B6 (uk)
DE (1) DE69414590T2 (uk)
DK (1) DK0720609T3 (uk)
ES (1) ES2123829T3 (uk)
FI (1) FI961270A (uk)
GR (1) GR3029354T3 (uk)
HK (1) HK1004219A1 (uk)
HR (1) HRP940575B1 (uk)
HU (1) HU217428B (uk)
IL (1) IL111002A (uk)
IS (1) IS4208A (uk)
NO (1) NO307830B1 (uk)
NZ (1) NZ273614A (uk)
OA (1) OA10576A (uk)
PE (1) PE18295A1 (uk)
PL (1) PL179585B1 (uk)
SI (1) SI0720609T1 (uk)
SK (1) SK280901B6 (uk)
UA (1) UA44711C2 (uk)
WO (1) WO1995008549A1 (uk)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
WO1996021661A1 (en) * 1995-01-12 1996-07-18 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
NZ333062A (en) * 1996-06-26 2000-06-23 Warner Lambert Co Use of [R,S]-[2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2yl methyl ester in the treatment of emesis
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998024441A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273806A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating substance use disorders
EP0942732B1 (en) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating movement disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
ES2227728T3 (es) * 1996-12-02 2005-04-01 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor de nk-1 para tratar trastornos de ests.
WO1998024442A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating sexual dysfunction
JP2001508412A (ja) * 1996-12-02 2001-06-26 メルク シヤープ エンド ドーム リミテツド 認識障害の治療のためのｎｋ−１受容体拮抗薬の使用
WO1998024443A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders
CA2273810A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
JP2001524960A (ja) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド 摂食障害を治療するためのｎｋ−１受容体拮抗薬の使用
EP0991622A1 (en) * 1997-06-27 2000-04-12 MERCK SHARP & DOHME LTD. Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
WO2002028853A1 (fr) * 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Compose de benzylamine, son procede de production et produit intermediaire correspondant
AU2002247127A1 (en) 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
CA2502178A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
CN100402508C (zh) * 2003-08-01 2008-07-16 东洋化成工业株式会社 烷氧基-(四唑-1-基)苯甲醛化合物及其生产方法
CN1580283A (zh) * 2003-08-13 2005-02-16 清华大学 一种检测核酸分子的方法
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
JP2006137691A (ja) * 2004-11-11 2006-06-01 Toyo Kasei Kogyo Co Ltd ２−アルコキシ−５−テトラゾリル−ベンズアルデヒド化合物の製造方法
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2310369A4 (en) * 2008-06-24 2014-02-19 Valeant Pharmaceuticals Int BENZYL OXYANILID DERIVATIVES SUITABLE AS SODIUM CHANNEL MODULATORS
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4371613A3 (en) 2018-02-26 2024-07-24 Ospedale San Raffaele S.r.l. Compounds for use in the treatment of ocular pain
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
CZ290475B6 (cs) * 1991-06-20 2002-07-17 Pfizer Inc. Fluoralkoxybenzylaminové deriváty heterocyklů obsahujících dusík, způsob jejich přípravy, meziprodukty tohoto postupu a pouľití těchto derivátů
PT675886E (pt) * 1992-12-10 2000-12-29 Pfizer Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them

Also Published As

Publication number Publication date
AU7697494A (en) 1995-04-10
SI0720609T1 (en) 1999-02-28
PE18295A1 (es) 1995-07-27
FI961270A0 (fi) 1996-03-19
DE69414590T2 (de) 1999-04-15
EP0720609B1 (en) 1998-11-11
GR3029354T3 (en) 1999-05-28
CN1061041C (zh) 2001-01-24
BG62169B1 (bg) 1999-04-30
IL111002A0 (en) 1994-11-28
CA2172529A1 (en) 1995-03-30
CO4290298A1 (es) 1996-04-17
AP495A (en) 1996-05-28
CZ285479B6 (cs) 1999-08-11
CN1135218A (zh) 1996-11-06
HU9600722D0 (en) 1996-05-28
BG100487A (bg) 1996-12-31
AP9400671A0 (en) 1994-10-31
HRP940575A2 (en) 1997-02-28
SK38396A3 (en) 1997-02-05
ATE173255T1 (de) 1998-11-15
US5703240A (en) 1997-12-30
DK0720609T3 (da) 1999-07-26
HU217428B (hu) 2000-01-28
IS4208A (is) 1995-03-23
ES2123829T3 (es) 1999-01-16
HK1004219A1 (en) 1998-11-20
US5843966A (en) 1998-12-01
SK280901B6 (sk) 2000-09-12
JPH09505275A (ja) 1997-05-27
PL313619A1 (en) 1996-07-08
NO961156D0 (no) 1996-03-21
IL111002A (en) 1998-09-24
PL179585B1 (pl) 2000-09-29
JP2865872B2 (ja) 1999-03-08
CZ83096A3 (en) 1996-09-11
JPH11106341A (ja) 1999-04-20
DE69414590D1 (de) 1998-12-17
NO307830B1 (no) 2000-06-05
UA44711C2 (uk) 2002-03-15
WO1995008549A1 (en) 1995-03-30
HRP940575B1 (en) 2000-06-30
EP0720609A1 (en) 1996-07-10
AU681190B2 (en) 1997-08-21
NO961156L (no) 1996-05-21
NZ273614A (en) 1997-09-22
FI961270A (fi) 1996-05-03
HUT75648A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
AP495A (en) Piperidine derivatives
EP0802912B1 (en) Piperidine derivatives having tachykinin antagonist activity
US5830892A (en) Piperidine and morphonline derivatives and their use as therapeutic agents
EP0799231B1 (en) Spiroketal derivatives, compositions containing them and their use as therapeutic agents
US5985896A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU715558B2 (en) Spiro-piperidine derivatives and their use as tachykinin antagonists
AU710873B2 (en) Morpholine derivatives and their use as therapeutic agents
US5962485A (en) N-(2-benzyloxy-1-phenethyl)-N-(2'-methoxyethyl)amino-methane compounds are useful as tachykinin antagonists
JPH09507484A (ja) 置換モルホリン誘導体およびその治療剤としての使用
JPH11502810A (ja) ニューロキニンアンタゴニストとしての３−ベンジルアミノ−２−フェニルピペリジン
JP3026945B2 (ja) ３−アザ及び３−オキサピペリドンタキキニン拮抗薬
JP3752130B2 (ja) 掻痒治療用新規４−アリールピペリジン誘導体
RU2136675C1 (ru) Производные 3-(5-тетразолилбензил)аминопиперидина, способы их получения и фармацевтическая композиция на их основе
FR2873373A1 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique